Biotech Business - December 14, 2023
Nykode announces expansion of oncology pipeline
Nykode Therapeutics has announced an expansion of the pipeline with a potential first-in-class preclinical oncology vaccine program aimed at preventing and treating colorectal cancer. “The potential first-in-class program reaffirms Nykode’s vision of building a balanced cancer vaccine portfolio. We are excited about the transformative power of our next-generation technology with the potential to reduce the […]
New Market - November 27, 2023
China NMPA’s approves Calliditas’ Nefecon
Calliditas’ partner Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. Everest also announced that, in addition to Nefecon’s approval in mainland China and Macau, it expects a decision on New Drug Application (NDA) […]
Biotech Business - October 2, 2023
New company aims to redefine cell therapy development
Alder Therapeutics is a newly founded preclinical phase stem cell therapy development company with the goal to reshape the cell therapy sector with a novel, reduced-risk approach and two cell therapy candidates for diseases with high unmet need. Alder Therapeutics was formed in 2022 to unlock the benefits of PSCs for patients across the world, […]
New Market - September 19, 2023
Orexo submits New Drug Application to FDA
Orexo has announced the submission of the New Drug Application (NDA) to the US Food and Drug Administration for OX124, a high-dose rescue medication for opioid overdose with nasal delivery. OX124, is based on Orexo’s drug delivery platform amorphOX and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl. […]
MedTech Business - September 6, 2023
Devyser and Thermo Fisher Scientific expand collaboration
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser’s post-transplant portfolio of NGS products. In addition to North America and Europe, Thermo Fisher will now exclusively market and sell Devyser’s transplantation products under combined brands also in Brazil. “We are very […]
MedTech Business - September 6, 2023
Senzime receives its largest US order to date
Senzime has announces an initial order from a California-based hospital system. The order consists of 110 TetraGraph monitors as well as consumables and is the result of a comprehensive clinical and competitive product evaluation. “This is another fantastic milestone for Senzime and our largest US order to date from one of the greatest hospital systems […]
